Laurus Labs Q4 PAT gallops 170% to Rs 297 cr

The drug maker's consolidated net profit soared 170% to Rs 297 crore on 68% surge in net sales to Rs 1,412 crore in Q4 FY21 over Q4 FY20.
On a consolidated basis, EBITDA grew 147% to Rs 477 crore in Q4 FY21 over Q4 FY20 while EBITDA margins stood at 34%. The board approved an interim dividend amounting to Re 0.80 per share.
The net profit soared 286% to Rs 984 crore on 70% surge in net sales to Rs 4,814 crore in the year ended March 2021 (FY21) over the year ended March 2020 (FY20). EBITDA grew 176% to Rs 1,573 crore in FY21 over FY20 while EBITDA margins stood at 33%.
The Reaseach and Development (R&D) expense stood at Rs 184 crore in FY21 which is 4% of its sales in FY21. The Generic FDF segment recorded a sale of Rs 430 crore, which is 30% of the contribution in Q4 and Rs 1,664 crore, 35% contribution in FY21.

Related Keywords

India ,Satyanarayana Chava ,Laurus Bio ,America Europe ,Richcore Life Sciences Pvt ,Drug Master Files ,Active Pharmaceutical Ingredients ,Laurus Labs ,Richcore Life Sciences Pvt Limited ,North America ,Custom Synthesis ,Capital Market ,Harmaceuticals Nec ,Pi ,Recombinant Products ,Harmaceutical Manufacturing ,Biotechnology Space ,United States ,Chief Executive Officer ,இந்தியா ,சத்தியநாராயணா சாவா ,லாரஸ் உயிர் ,அமெரிக்கா யூரோப் ,மருந்து குரு கோப்புகள் ,செயலில் மருந்து பொருட்கள் ,லாரஸ் ஆய்வகங்கள் ,வடக்கு அமெரிக்கா ,தனிப்பயன் தொகுப்பு ,மூலதனம் சந்தை ,பி ,ந்திய ,